Cargando…

Chromosomal instability and acquired drug resistance in multiple myeloma

Chromosomal instability (CIN) is an important hallmark of human cancer. CIN not only contributes to all stages of tumor development (initiation, promotion and progression) but also drives, in large measure, the acquisition of drug resistance by cancer cells. Although CIN is a cornerstone of the comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Wang, Zhang, Yi, Chen, Ruini, Tian, Zhidan, Zhai, Yongpin, Janz, Siegfried, Gu, Chunyan, Yang, Ye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652852/ https://www.ncbi.nlm.nih.gov/pubmed/29100463 http://dx.doi.org/10.18632/oncotarget.20829

Ejemplares similares

CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2021)

Germline Risk Contribution to Genomic Instability in Multiple Myeloma
por: Janz, Siegfried, et al.
Publicado: (2019)

An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
por: Sawyer, Jeffrey R., et al.
Publicado: (2019)

NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma
por: Yang, Ye, et al.
Publicado: (2014)

Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2018)

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
por: Franqui-Machin, Reinaldo, et al.
Publicado: (2015)

Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2019)

BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability
por: Tang, Xiaozhu, et al.
Publicado: (2021)

Drug Targeting of Genomic Instability in Multiple Myeloma
por: Beksac, Meral, et al.
Publicado: (2020)

NAT10 promotes cell proliferation by acetylating CEP170 mRNA to enhance translation efficiency in multiple myeloma
por: Wei, Rongfang, et al.
Publicado: (2022)

Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma
por: Innao, Vanessa, et al.
Publicado: (2021)

Looking into Endoplasmic Reticulum Stress: The Key to Drug-Resistance of Multiple Myeloma?
por: Wang, Guangqi, et al.
Publicado: (2022)

A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma
por: Chung, Tae-Hoon, et al.
Publicado: (2013)

In vivo acquired sorafenib-resistant patient-derived tumor model displays alternative angiogenic pathways, multi-drug resistance and chromosome instability
por: Hu, Gang, et al.
Publicado: (2018)

Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma
por: Locher, Maurus, et al.
Publicado: (2022)

Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma
por: Fujibayashi, Yuto, et al.
Publicado: (2020)

CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma
por: Han, Seong-Su, et al.
Publicado: (2015)

Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma
por: Guo, Mengjie, et al.
Publicado: (2021)

HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA
por: Jiang, Fengjie, et al.
Publicado: (2021)

Genome Instability in Multiple Myeloma: Facts and Factors
por: Aksenova, Anna Y., et al.
Publicado: (2021)

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
por: Turner, Joel G., et al.
Publicado: (2016)

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
por: Gu, Chunyan, et al.
Publicado: (2018)

Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma
por: Dou, Renjie, et al.
Publicado: (2021)

Cancer drug resistance in multiple myeloma
por: Uckun, Fatih M.
Publicado: (2022)

Acquired activated protein C resistance and thrombosis in multiple myeloma patients
por: Hugo, Jiménez-Zepeda Víctor, et al.
Publicado: (2006)

Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
por: Chen, Ying, et al.
Publicado: (2020)

BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling
por: Gu, Chunyan, et al.
Publicado: (2017)

Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma
por: Cagnetta, Antonia, et al.
Publicado: (2015)

The Role of DNA Repair in Genomic Instability of Multiple Myeloma
por: Ali, Jana Yasser Hafez, et al.
Publicado: (2022)

Molecular mechanisms in multiple myeloma drug resistance
por: Nikesitch, Nicholas, et al.
Publicado: (2016)

Corrigendum: Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
por: Chen, Ying, et al.
Publicado: (2021)

WDR26 and MTF2 are therapeutic targets in multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2021)

Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

Splicing factor arginine/serine‐rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome‐based cellular communication
por: Zhang, Yuanjiao, et al.
Publicado: (2022)

Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway
por: Chen, Yan, et al.
Publicado: (2015)

S186: ACQUIRED RESISTANCE TO BISPECIFIC ANTIBODIES BY GENETIC OR EPIGENETIC INACTIVATION OF THE TARGET IN MULTIPLE MYELOMA
por: Derrien, Jennifer, et al.
Publicado: (2023)

Genomic Instability and Replicative Stress in Multiple Myeloma: The Final Curtain?
por: Botrugno, Oronza A., et al.
Publicado: (2021)

MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment
por: Gu, Chunyan, et al.
Publicado: (2015)

The Adaptability of Chromosomal Instability in Cancer Therapy and Resistance
por: Carloni, Vinicio, et al.
Publicado: (2022)

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
por: Yang, Wen-Chi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_32unh3742p55sefeqap4c3vb0n